Remove 2022 Remove Clinical Trials Remove Safety Remove Topical
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. Clinical Trials and Human Subject Protections. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects. 1] Letter from Sens.

article thumbnail

Harvard Law Review: Patents on Psychedelics: The Next Legal Battlefront of Drug Development

Cannabis Law Report

20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Essay by I. war on drugs. 15 × 15.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IGC Reports Financial Results for the September 30, 2021 Quarter

Cannabis Law Report

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. During the six months ended September 30, 2021, the Company raised approximately $4.1

article thumbnail

Green Light Law Group: Oregon Psilocybin Advisory Board Approves Training and Products Recommendations

Cannabis Law Report

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). You can contact Brett Mulligan at ? info@gl-lg.com ? or 503-488-5424.

Law 52
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.

History 119
article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

article thumbnail

CBD Market Report

Project CBD

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. The labs analyzed 35 oils, 40 topical products, 40 edibles, 22 beverages, 55 pet products, and 29 coffee or tea products.

CBD 144